As per the restructured agreement, Merck has acquired full control of the development and worldwide commercialisation of Ridaforolimus. Ariad is expected to receive a $50m upfront fee and
Pharmacokinetic data from the initial Phase I trial of BNC210 reported on March 3, 2010 indicated that a plateau of absorption of BNC210 was observed at doses between
The addition of ABS scientists and resources establishes UBC with the presence and operational reach in the New England biomedical corridor and adds to its portfolio of scientific
The Intrepid2566 trial is expected to seek to enroll a total of 260 patients with moderate to severe brain injury. Patients will be randomised 2:1 for drug and
LX1031 is an oral, serotonin synthesis inhibitor that acts locally in the gastrointestinal tract targeting tryptophan hydroxylase (TPH), an enzyme necessary for the production of serotonin. LX1031 is
TB-402 is a new, long acting anticoagulant that is being developed as a single injection for the prevention of venous thromboembolism (VTE) following orthopaedic surgery. The Phase II
The latest order brings the overall value of tenders awarded to Crucell for the period of 2010-2012 to $410m. This is in addition to the $500m obtained over
Synairgen said that the issued patent is part of a patent portfolio owned by the University of Southampton, which is exclusively licensed to Synairgen. Reportedly, laboratory experiments were
Under the terms of the agreement, Boehringer Ingelheim will pay Micromet an upfront cash payment of approximately $6.6m. Micromet will be eligible to receive development and regulatory milestone
Under the agreed terms Intercell is expected to pay EUR15m to Cytos. Intercell is expected to own certain unpartnered monoclonal antibody assets, including promising pre-clinical anti-infective antibody candidates
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.